Loading...

Lipocine

Nasdaq:LPCN
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LPCN
Nasdaq
$31M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
LPCN Share Price and Events
7 Day Returns
-10%
NasdaqCM:LPCN
-1.5%
US Pharmaceuticals
-3.4%
US Market
1 Year Returns
-59.7%
NasdaqCM:LPCN
17.7%
US Pharmaceuticals
10%
US Market
LPCN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lipocine (LPCN) -10% 19% 2.9% -59.7% -88.9% -83.9%
US Pharmaceuticals -1.5% 2.6% 5.6% 17.7% 32.6% 54%
US Market -3.4% -0.6% -4.3% 10% 55.8% 96.7%
1 Year Return vs Industry and Market
  • LPCN underperformed the Pharmaceuticals industry which returned 17.7% over the past year.
  • LPCN underperformed the Market in United States of America which returned 10% over the past year.
Price Volatility
LPCN
Industry
5yr Volatility vs Market

LPCN Value

 Is Lipocine undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Lipocine to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Lipocine.

NasdaqCM:LPCN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:LPCN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 3%
Equity Risk Premium S&P Global 7.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.693 (1 + (1- 21%) (32.98%))
0.873
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.87
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.95% + (0.873 * 7.05%)
9.11%

Discounted Cash Flow Calculation for NasdaqCM:LPCN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Lipocine is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqCM:LPCN DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) -16.37 -8.32 1.48 6.32 7.33
Source Analyst x1 Analyst x1 Analyst x1 Analyst x1 Est @ 16%, capped from 27.87%
Present Value
Discounted (@ 9.11%)
-15.00 -6.99 1.14 4.46 4.74
Present value of next 5 years cash flows $-11.65
NasdaqCM:LPCN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $7.33 × (1 + 2.95%) ÷ (9.11% – 2.95%)
$122.57
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $122.57 ÷ (1 + 9.11%)5
$79.28
NasdaqCM:LPCN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $-11.65 + $79.28
$67.63
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $67.63 / 21.46
$3.15
NasdaqCM:LPCN Discount to Share Price
Calculation Result
Value per share (USD) From above. $3.15
Current discount Discount to share price of $1.44
= -1 x ($1.44 - $3.15) / $3.15
54.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Lipocine is available for.
Intrinsic value
>50%
Share price is $1.44 vs Future cash flow value of $3.15
Current Discount Checks
For Lipocine to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Lipocine's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Lipocine's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lipocine's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lipocine's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:LPCN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.65
NasdaqCM:LPCN Share Price ** NasdaqCM (2018-11-16) in USD $1.44
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 27 Publicly-Listed Pharmaceuticals Companies 20.43x
United States of America Market PE Ratio Median Figure of 2,977 Publicly-Listed Companies 17.93x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lipocine.

NasdaqCM:LPCN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:LPCN Share Price ÷ EPS (both in USD)

= 1.44 ÷ -0.65

-2.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lipocine is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Lipocine is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Lipocine's expected growth come at a high price?
Raw Data
NasdaqCM:LPCN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-75%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 22 Publicly-Listed Pharmaceuticals Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,096 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Lipocine, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lipocine's assets?
Raw Data
NasdaqCM:LPCN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $0.55
NasdaqCM:LPCN Share Price * NasdaqCM (2018-11-16) in USD $1.44
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 164 Publicly-Listed Pharmaceuticals Companies 2.84x
United States of America Market PB Ratio Median Figure of 4,980 Publicly-Listed Companies 1.85x
NasdaqCM:LPCN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:LPCN Share Price ÷ Book Value per Share (both in USD)

= 1.44 ÷ 0.55

2.61x

* Primary Listing of Lipocine.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lipocine is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Lipocine's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Lipocine has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LPCN Future Performance

 How is Lipocine expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-75%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lipocine expected to grow at an attractive rate?
  • Unable to compare Lipocine's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Lipocine's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Lipocine's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:LPCN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:LPCN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -75%
NasdaqCM:LPCN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 74.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.2%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:LPCN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:LPCN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 58 1
2021-12-31 42 1
2020-12-31 12 1
2019-12-31 0 -27 3
2018-12-31 0 -11 2
NasdaqCM:LPCN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 0 -14 -14
2018-06-30 0 -15 -16
2018-03-31 0 -17 -19
2017-12-31 -17 -21
2017-09-30 -15 -19
2017-06-30 -14 -17
2017-03-31 -15 -17
2016-12-31 -18 -19
2016-09-30 -19 -21
2016-06-30 -20 -24
2016-03-31 -19 -22
2015-12-31 -15 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Lipocine is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Lipocine's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:LPCN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Lipocine Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:LPCN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31 -1.09 -0.80 -1.38 2.00
2018-12-31 -0.53 -0.49 -0.56 2.00
NasdaqCM:LPCN Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.65
2018-06-30 -0.76
2018-03-31 -0.91
2017-12-31 -1.05
2017-09-30 -0.96
2017-06-30 -0.92
2017-03-31 -0.92
2016-12-31 -1.04
2016-09-30 -1.13
2016-06-30 -1.30
2016-03-31 -1.25
2015-12-31 -1.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lipocine will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Lipocine's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lipocine has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LPCN Past Performance

  How has Lipocine performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lipocine's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lipocine does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Lipocine's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Lipocine's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Lipocine's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lipocine Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:LPCN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.43 -13.77 7.93 2.43
2018-06-30 0.43 -16.01 9.72 2.52
2018-03-31 0.43 -18.84 10.08 2.51
2017-12-31 -20.98 10.21 2.52
2017-09-30 -18.62 7.92 2.40
2017-06-30 -17.15 6.60 2.34
2017-03-31 -16.82 7.81 2.35
2016-12-31 -18.97 10.38 2.58
2016-09-30 -20.64 10.97 0.53
2016-06-30 -23.78 11.27 0.59
2016-03-31 -22.26 9.14 0.58
2015-12-31 -18.21 5.80 2.55
2015-09-30 -17.61 5.04 2.61
2015-06-30 -15.34 4.21 2.66
2015-03-31 -18.06 4.13 2.43
2014-12-31 -20.37 5.00 2.59
2014-09-30 -20.72 4.87 2.28
2014-06-30 -20.10 5.18 2.22
2014-03-31 -14.51 4.85 2.25
2013-12-31 -10.59 3.64 2.15
2013-09-30 0.00 -7.06 2.90 2.17
2013-06-30 0.00 -4.48 2.18 1.96
2013-03-31 0.00 -4.21 1.81 2.02
2012-12-31 7.71 3.80 1.55 1.91
2011-12-31 3.09 -2.25 2.31 2.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Lipocine has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Lipocine has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Lipocine improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Lipocine's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lipocine has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LPCN Health

 How is Lipocine's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lipocine's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lipocine is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Lipocine's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Lipocine's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lipocine Company Filings, last reported 1 month ago.

NasdaqCM:LPCN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 11.76 10.19 16.88
2018-06-30 13.88 10.13 20.09
2018-03-31 16.67 10.06 27.76
2017-12-31 18.98 0.00 21.47
2017-09-30 23.77 0.00 25.68
2017-06-30 25.15 0.00 27.83
2017-03-31 24.88 0.00 26.80
2016-12-31 26.02 0.00 26.84
2016-09-30 27.98 0.00 28.84
2016-06-30 30.76 0.00 32.94
2016-03-31 35.78 0.00 38.21
2015-12-31 41.99 0.00 44.38
2015-09-30 46.25 0.00 41.79
2015-06-30 52.13 0.00 43.87
2015-03-31 23.72 0.00 24.76
2014-12-31 26.36 0.00 27.67
2014-09-30 29.96 0.00 31.67
2014-06-30 33.82 0.00 34.16
2014-03-31 40.60 0.00 41.77
2013-12-31 44.82 0.00 45.26
2013-09-30 35.54 0.00 36.84
2013-06-30 3.14 0.00 3.61
2013-03-31 4.44 0.00 4.62
2012-12-31 5.32 0.00 5.38
2011-12-31 1.30 0.00 8.57
  • Lipocine's level of debt (86.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 86.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Lipocine has sufficient cash runway for 1.2 years based on current free cash flow.
  • Lipocine has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 9.9% each year.
X
Financial health checks
We assess Lipocine's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lipocine has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LPCN Dividends

 What is Lipocine's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lipocine dividends.
If you bought $2,000 of Lipocine shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lipocine's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lipocine's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:LPCN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1977 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:LPCN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lipocine has not reported any payouts.
  • Unable to verify if Lipocine's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lipocine's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lipocine has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Lipocine's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lipocine afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lipocine has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LPCN Management

 What is the CEO of Lipocine's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mahesh Patel
COMPENSATION $1,258,622
AGE 61
TENURE AS CEO 21.8 years
CEO Bio

Dr. Mahesh V. Patel, Ph.D. co-founded Lipocine Inc. in 1997 and has also been its President and Chief Executive Officer since 1997. Dr. Patel has more than fifteen years of technology and product development experience in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine, he led drug delivery research and development at Pharmacia and Upjohn, Kalamazoo, MI. His areas of expertise include strategic planning, technology assessment/development, technical management and product research and development. Dr. Patel has been the Chairman of Lipocine Inc. since January 6, 2014 and its Director since 1997. Dr. Patel received a B.Pharm from Karnataka University in India. Dr. Patel received his M.S. in physical pharmacy at the University of Cincinnati and his Ph.D. in pharmaceutics from the University of Utah.

CEO Compensation
  • Mahesh's compensation has been consistent with company performance over the past year.
  • Mahesh's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Lipocine management team in years:

4.3
Average Tenure
55
Average Age
  • The tenure for the Lipocine management team is about average.
Management Team

Mahesh Patel

TITLE
Co-Founder
COMPENSATION
$1M
AGE
61
TENURE
21.8 yrs

Morgan Brown

TITLE
Executive VP
COMPENSATION
$759K
AGE
50
TENURE
5.2 yrs

Logan Morse

TITLE
Vice President of Sales
COMPENSATION
$633K
AGE
48
TENURE
1.6 yrs

Nachiappan Chidambaram

TITLE
Vice President of Product Development
COMPENSATION
$472K
AGE
49
TENURE
4.3 yrs

William Higuchi

TITLE
Chief Scientific Consultant
COMPENSATION
$417K
AGE
87

Anthony DelConte

TITLE
Chief Medical Director
AGE
60
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Lipocine board of directors in years:

4.8
Average Tenure
60
Average Age
  • The tenure for the Lipocine board of directors is about average.
Board of Directors

Mahesh Patel

TITLE
Co-Founder
COMPENSATION
$1M
AGE
61
TENURE
4.8 yrs

Stephen Hill

TITLE
Lead Independent Director
COMPENSATION
$111K
AGE
60

Jeffrey Fink

TITLE
Independent Director
COMPENSATION
$79K
AGE
60
TENURE
4.8 yrs

George Zografi

TITLE
Member of Scientific Advisory Board

Tsuneji Nagai

TITLE
Member of Scientific Advisory Board

Alan Hofmann

TITLE
Member of Scientific Advisory Board

Norman Ho

TITLE
Member of Scientific Advisory Board

Rex Hjelm

TITLE
Member of Scientific Advisory Board

John Higuchi

TITLE
Director
COMPENSATION
$53K
AGE
50
TENURE
15.8 yrs

Ron Borchardt

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Lipocine's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lipocine has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LPCN News

External News
Loading...
Simply Wall St News

Does Lipocine Inc's (NASDAQ:LPCN) CEO Pay Compare Well With Peers?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Mahesh Patel's Compensation Compare With Similar Sized Companies. … As you can see, Mahesh Patel is paid more than the median CEO pay at companies of a similar size, in the same market

Simply Wall St -

Is There An Opportunity With Lipocine Inc's (NASDAQ:LPCN) 25.31% Undervaluation?

by estimating the company's future cash flows and discounting them to their present value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

When Will Lipocine Inc (NASDAQ:LPCN) Become Profitable?

Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. … The US$27.01m market-cap posted a loss in its most recent financial year of -US$20.98m and a latest trailing-twelve-month loss of -US$18.84m shrinking the gap between loss and breakeven? … I’ve put together a brief outline of industry analyst expectations for LPCN, its year of breakeven and its implied growth rate

Simply Wall St -

What Should You Know About Lipocine Inc's (NASDAQ:LPCN) Earnings Trend?

In December 2017, Lipocine Inc (NASDAQ:LPCN) announced its most recent earnings update, which confirmed company earnings became less negative compared to the previous year's level as a result of recent tailwinds Below, I've presented key growth figures on how market analysts view Lipocine's earnings growth trajectory over the next couple of years and whether the future looks brighter. … The slope of this line is the rate of earnings growth, which in this case is 56.60%. … This means, we can expect Lipocine will grow its earnings by 56.60% every year for the next few years.

Simply Wall St -

Who Owns Lipocine Inc (NASDAQ:LPCN)?

Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … 5.85% ownership makes insiders an important shareholder group. … Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Does Lipocine Inc's (NASDAQ:LPCN) CEO Salary Reflect Performance?

Check out our latest analysis for Lipocine Did Patel create value? … Recently, LPCN released negative earnings of -US$18.62M. … Normally I would use earnings and market cap to account for variations in performance, however, LPCN's negative earnings reduces the effectiveness of this method.

Simply Wall St -

When Will Lipocine Inc (NASDAQ:LPCN) Become Profitable?

In this article, I will touch on the expectations for LPCN’s growth and when analysts expect the company to become profitable. … Working backwards from analyst estimates, it turns out that they expect the company to grow 55.33% year-on-year, on average, which is extremely buoyant. … Next Steps: There are too many aspects of LPCN to cover in one brief article, but the key fundamentals for the company can all be found in one place – LPCN’s company page on Simply Wall St.

Simply Wall St -

Want To Invest In Lipocine Inc (NASDAQ:LPCN)? Here's How It Performed Lately

This means Lipocine has historically performed better than recently, although it seems like earnings are now heading back towards a more favorable position once more. … NasdaqCM:LPCN Income Statement Feb 13th 18 We can further assess Lipocine's loss by looking at what the industry has been experiencing over the past few years. … This means though Lipocine is currently running a loss, it may have benefited from industry tailwinds, moving earnings towards to right direction.What does this mean?

Simply Wall St -

LPCN Company Info

Map
Description

Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company’s pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that is currently in Phase II testing; and LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Details
Name: Lipocine Inc.
LPCN
Exchange: NasdaqCM
Founded:
$30,908,203
21,464,030
Website: http://www.lipocine.com
Address: Lipocine Inc.
675 Arapeen Drive,
Suite 202,
Salt Lake City,
Utah, 84108,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM LPCN Common Stock Nasdaq Capital Market US USD 26. Jul 2013
DB 2VT Common Stock Deutsche Boerse AG DE EUR 26. Jul 2013
Number of employees
Current staff
Staff numbers
14
Lipocine employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/19 02:30
End of day share price update: 2018/11/16 00:00
Last estimates confirmation: 2018/11/09
Last earnings filing: 2018/11/07
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.